HVAX Technolog. Q3 FY26 Earnings Analysis

- HVAX Technologies aims for a sustained revenue growth of around 35% year-on-year over the next couple of years. - The company is focused on expanding its presence in global markets and entering new segments like hospital, semiconductor, and solar industries. - Current order book is INR350 crores with a healthy pipeline of INR650-680 crores, indicating strong future execution visibility. - H2 FY '26 is expected to be stronger than H1 FY '26 in terms of revenue, supported by installation and design-led projects. - Export orders constitute around 70%-85% of revenues, with better margin profiles driving growth. - Strategic acquisitions (e.g., Krew Instruments) and partnerships aim to diversify offerings and accelerate growth. - The company is investing in upskilling human resources to support capacity utilization and growth. - Overall, HVAX is well-positioned for sustained, profitable growth built on expanding order book, industry diversification, and global market penetration.

- HVAX Technologies targets a revenue growth of around 35% year-on-year for the next couple of years. - Operating margins are expected to be sustainable or improve slightly compared to previous years. - EBITDA margins may face short-term pressure due to increased sales and marketing expenses but are expected to stabilize and improve operationally. - The company's focus on expanding design-built projects (currently ~15-20% of revenue) aims to enhance margins going forward. - Diversification into hospital, semiconductor, and solar sectors may impact margins; however, hospital segment margins are expected to be equal or better than pharma. - The acquisition of Krew Instruments and other strategic partnerships are anticipated to drive synergies, cross-selling, and profitable growth. - Overall, management is cautiously optimistic about continued profitable growth, operational excellence, and sustained margin expansion.

- HVAX Technologies Ltd is actively pursuing strategic acquisitions to diversify into new industries such as hospitals, semiconductors, and solar energy. - The recent acquisition of Krew Instruments provides a direct entry into the hospital segment, enhancing growth potential through synergies and expanding the customer base. - The company is cautious about new industry margins, implying careful evaluation of future capital investments. - They are focused on expanding design-build project capabilities, especially in export markets, by establishing an in-house design and consultancy team. - The company may raise funds via debt or equity depending on the size and nature of future acquisitions but intends to avoid unnecessary debt. - Emphasis is on acquiring companies that provide strategic value and fit well within existing business to ensure sustainable growth. - There is no explicit mention of large-scale capex for manufacturing; emphasis is on service, design, and integration capabilities expansion.

- HVAX Technologies Ltd currently does not have a fixed plan to raise funds through debt or equity. - Fundraising decisions depend on the size and nature of acquisitions they pursue. - The company intends to keep acquisitions small and is cautious about raising debt or equity. - Any debt or equity issuance will be decided based on the specific requirements related to potential acquisitions. - Management emphasized they are particular about the amount and companies they acquire, which influences their fundraising approach.

- The current order book is around INR 350 crores, primarily comprising pharma and hospital projects (98%-99% pharma). - Out of the order book, approximately 70%-75% are export orders, with 85% of revenues currently from exports. - The INR 350 crores order book is expected to be executed over one to two years. - There is also mention of a pipeline of INR 680 crores, which is realistically convertible into FY 2026. - The company expects stronger execution and revenue in H2 FY '26 as design-led and installation activities pick up. - Diversification efforts are ongoing into sectors like solar and semiconductors, but pharma and hospital segments remain dominant for now. - Future sector mix is expected to diversify but cannot be precisely specified yet.